Thursday 16 October, 2025
Introduction: Lenacapavir (LEN) is a novel long-acting, first-in-class, selective inhibitor of HIV-1 capsid function, currently approved for multidrug resistant HIV-1…
Read morePoster: Drug/Disease Modelling - Infection
Viral dynamic modeling of nirmatrelvir against SARS-CoV-2 in an in vitro infection model
Thursday 16 October, 2025
Objectives: The coronavirus disease 2019 (COVID-19) pandemic caused by the RNA-virus SARS-CoV-2 has shown the development of new antiviral agents….
Read moreDelpazolid population pharmacokinetics and pharmacodynamics in patients with pulmonary tuberculosis
Thursday 16 October, 2025
Introduction: Linezolid is currently recommended for the treatment of multidrug-resistant tuberculosis (MDR-TB) by the WHO. However, this drug is associated with…
Read moreTotal and unbound flucloxacillin population pharmacokinetics in patients with Staphylococcus aureus bloodstream infection
Thursday 16 October, 2025
Objectives: Target attainment of flucloxacillin in patients with Staphylococcus aureus bloodstream infections (BSI) is challenging due to the high inter-individual…
Read moreModelling & simulation of biomarkers during anti-HIV monotherapy treatment
Thursday 16 October, 2025
Introduction: Since its first discovery, the human immunodeficiency virus (HIV) has infected more than 70M people worldwide and 35M have died….
Read moreEvaluating empirical dose-response relationships and dosing strategies of bacteriophage therapy using a mechanism-based modeling approach
Thursday 16 October, 2025
Background and objectives: Bacteriophages, or phages, are viruses capable of infecting and replicating within bacterial cells, and ultimately lysing them….
Read morePreclinical population pharmacokinetic modelling of skin target site exposure of DNDI-0690 and DNDI-6148 in the treatment of cutaneous leishmaniasis
Thursday 16 October, 2025
Introduction: Cutaneous Leishmaniasis (CL) represents the most common disease manifestation of the neglected tropical disease leishmaniasis, caused by various species of…
Read moreCombined population PK modelling of cefepime and enmetazobactam to characterize their individual and combined PK from the phase 1 to 3 studies
Thursday 16 October, 2025
Introduction: Cefepime (FEP)-enmetazobactam (ENM) is a new fixed dose combination treatment for the treatment of urinary tract infections (cUTI) (and nosocomial…
Read moreUnderstanding Population Heterogeneity in Vaccine-induced Immunity: A Mechanistic Model for Immune Fingerprinting
Thursday 16 October, 2025
Objectives: : Vaccines are pivotal in combating infectious diseases, saving millions of lives worldwide and vastly improving public health. Despite their…
Read moreExternal evaluation of a population pharmacokinetic (POP-PK) model of Cabotegravir HIV-1-infected patients treated with long-acting Cabotegravir/Rilpivirine (LA CAB-RPV)
Thursday 16 October, 2025
Objectives: Cabotegravir is a potent integrase strand transfer inhibitor recently approved as a long-acting (LA) intramuscular (IM) injection in combination…
Read more